428 results on '"Wymann, Matthias P."'
Search Results
2. Nuclear and cytosolic fractions of SOX2 synergize as transcriptional and translational co-regulators of cell fate
3. The role of PI3Kγ in the immune system: new insights and translational implications
4. Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
5. Rapid, potent, and persistent covalent chemical probes to deconvolute PI3Kα signaling.
6. Specific Requirement of the p84/p110γ Complex of PI3Kγ for Antibody‐Activated, Inducible Cross‐Presentation in Murine Type 2 DCs.
7. Two-drug trick to target the brain blocks toxicity in the body
8. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex
9. Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
10. An evolutionary-conserved VPS34-PIKfyve-TRPML1-Myosin II axis regulates the speed of amoeboid cell migration
11. The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
12. A class of highly selective inhibitors bind to an active state of PI3Kγ
13. Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB
14. Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation
15. Bifurcation of Lipid and Protein Kinase Signals of PI3Kγ to the Protein Kinases PKB and MAPK
16. Supplementary Data from Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
17. Data from Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
18. Table S2 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
19. Supplementary figures, table legends, Table S1, S9 from PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
20. Stereospecific Synthesis of Substituted Sulfamidates as Privileged Morpholine Building Blocks
21. Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy
22. Chemical Development of Intracellular Protein Heterodimerizers
23. C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms
24. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kγ-dependent fluid-phase pinocytosis of native LDL
25. PIЗKγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance
26. Ras Is an Indispensable Coregulator of the Class ${\rm I}_{{\rm B}}$ Phosphoinositide 3-Kinase p87/p110γ
27. Integrating Cardiac PIP 3 and cAMP Signaling through a PKA Anchoring Function of p110γ
28. Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
29. Stereospecific Synthesis of Substituted Sulfamidates as Privileged Morpholine Building Blocks.
30. Suppression of caspase 8 activity by a coronin 1–PI3Kδ pathway promotes T cell survival independently of TCR and IL-7 signaling
31. Targeting Phosphoinositide 3-Kinase – Five Decades of Chemical Space Exploration
32. Wortmannin Binds Specifically to 1-Phosphatidylinositol 3-Kinase While Inhibiting Guanine Nucleotide-Binding Protein-Coupled Receptor Signaling in Neutrophil Leukocytes
33. N-Formyl Peptide Receptors in Human Neutrophils Display Distinct Membrane Distribution and Lateral Mobility When Labeled with Agonist and Antagonist
34. Abstract 1378: A novel, highly potent PI3Kα covalent inhibitor deconvolutes class I PI3K isoforms in cancer cells
35. Abstract 1377: Volume scanning, a rational approach to covalent PI3Kα inhibitors
36. Chemical and Structural Strategies to Selectively Target mTOR Kinase
37. Abstract 293: Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitors suitable for the treatment of CNS disorders
38. Targeting phosphoinositide 3-kinase—Moving towards therapy
39. Targeting PI3K in neuroblastoma
40. Elastin-derived peptides potentiate atherosclerosis through the immune Neu1-PI3Kγ pathway
41. Ras is an indispensable coregulator of the class [I.sub.B] phosphoinositide 3-kinase p87/p110[gamma]
42. Lipid signalling in disease
43. Inactivation of PI3Kγ and PI3Kδ distorts T-cell development and causes multiple organ inflammation
44. The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax
45. Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors
46. Author response: Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors
47. Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability
48. Defective dendritic cell migration and activation of adaptive immunity in PI3Kγ‐deficient mice
49. Blockade of PI3K[gamma] suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
50. Membrane dynamics in physiology and disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.